Fig. 4

Association of marker levels with renal and lung involvement of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). a Comparison of transketolase (TKT) and CD93 levels between patients with AAV with (n = 120) and without (n = 49) renal involvement before treatment. b Comparison of TKT and CD93 levels at baseline between patients with AAV who did (n = 15) and did not (n = 97) develop end-stage renal disease (ESRD) at 6 months after the start of treatment. c Comparison of tenascin C (TNC) levels between patients with AAV with and without lung involvement before treatment. The numbers of patients with only lung infiltration, only nodules or cavities, and nonlung involvement were 25, 11, and 95, respectively. Statistical analysis is described in the legend of Fig. 3. *p < 0.05; ***p < 0.001. n.s. Not significant